title: A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.
abstract: Pharmacogenomics (PGx) tests have the potential of improving the effectiveness of expensive new drugs by predicting the likelihood, for a particular patient, to respond to a treatment. The objective of this study was to develop a pharmacoeconomic model to determine the characteristics and the cost-effectiveness of a hypothetical PGx test, which would identify patients who are most likely to respond to an expensive treatment for chronic heart failure. For this purpose, we chose the example of ivabradine. Our results suggest that the use of a PGx test that could select a subgroup of patients to be treated with an expensive drug has the potential to provide more efficient drug utilization.
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
authors.forename: Ange C
authors.initials: AC
authors.lastname: Iliza
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.|Division of General Cardiology, Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
authors.forename: Alexis
authors.initials: A
authors.lastname: Matteau
authors.affiliation: McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada.|Programs for Assessment of Technology in Health, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
authors.forename: Jason R
authors.initials: JR
authors.lastname: Guertin
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
authors.forename: Dominic
authors.initials: D
authors.lastname: Mitchell
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
authors.forename: Fiorella
authors.initials: F
authors.lastname: Fanton-Aita
authors.affiliation: Beaulieu-Saucier Pharmacogenomics Centre, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.
authors.forename: Anick
authors.initials: A
authors.lastname: Dubois
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Beaulieu-Saucier Pharmacogenomics Centre, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Dubé
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Beaulieu-Saucier Pharmacogenomics Centre, Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
authors.affiliation: Faculté de médicine, Université de Montréal, Montréal, Québec, Canada.|Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
authors.forename: Jacques
authors.initials: J
authors.lastname: LeLorier
keywords: Markov model; New York Heart Association; cardiovascular diseases; chronic heart failure; cost%ndash;effectiveness; pharmacogenomics tests; quality-adjusted life years